Peter Gottlieb
Concepts (553)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 140 | 2025 | 3629 | 6.680 |
Why?
| Insulin | 52 | 2025 | 2329 | 2.750 |
Why?
| C-Peptide | 31 | 2025 | 163 | 2.080 |
Why?
| Islets of Langerhans | 24 | 2025 | 791 | 1.900 |
Why?
| Insulin-Secreting Cells | 18 | 2021 | 367 | 1.620 |
Why?
| Autoantibodies | 36 | 2025 | 1468 | 1.550 |
Why?
| Hypoglycemic Agents | 21 | 2024 | 1220 | 1.540 |
Why?
| B-Lymphocytes | 10 | 2025 | 816 | 1.200 |
Why?
| T-Lymphocytes | 25 | 2025 | 1937 | 1.030 |
Why?
| Antilymphocyte Serum | 8 | 2021 | 63 | 1.010 |
Why?
| CD4-Positive T-Lymphocytes | 14 | 2025 | 1058 | 1.000 |
Why?
| Autoantigens | 15 | 2021 | 420 | 0.970 |
Why?
| Monitoring, Ambulatory | 4 | 2010 | 83 | 0.960 |
Why?
| Blood Glucose | 16 | 2024 | 2102 | 0.930 |
Why?
| Autoimmunity | 19 | 2023 | 863 | 0.930 |
Why?
| Antibodies, Monoclonal, Humanized | 12 | 2023 | 756 | 0.860 |
Why?
| Proinsulin | 7 | 2024 | 52 | 0.810 |
Why?
| Immunosuppressive Agents | 9 | 2023 | 858 | 0.790 |
Why?
| Clinical Trials as Topic | 11 | 2020 | 1005 | 0.750 |
Why?
| Blood Glucose Self-Monitoring | 4 | 2010 | 601 | 0.700 |
Why?
| Addison Disease | 8 | 2012 | 43 | 0.670 |
Why?
| Adolescent | 73 | 2025 | 20415 | 0.670 |
Why?
| Immunologic Factors | 7 | 2019 | 229 | 0.640 |
Why?
| Adult | 89 | 2025 | 35607 | 0.640 |
Why?
| CD4 Antigens | 2 | 2013 | 137 | 0.640 |
Why?
| Humans | 157 | 2025 | 129687 | 0.640 |
Why?
| Preventive Medicine | 2 | 2018 | 41 | 0.610 |
Why?
| Polyendocrinopathies, Autoimmune | 3 | 2010 | 18 | 0.610 |
Why?
| Child | 66 | 2025 | 20882 | 0.600 |
Why?
| Prediabetic State | 7 | 2018 | 244 | 0.600 |
Why?
| Diabetes Mellitus, Type 2 | 6 | 2020 | 2443 | 0.590 |
Why?
| Peptide Fragments | 13 | 2024 | 695 | 0.560 |
Why?
| Young Adult | 47 | 2025 | 12457 | 0.560 |
Why?
| Insulin Antibodies | 6 | 2022 | 105 | 0.550 |
Why?
| CD8-Positive T-Lymphocytes | 10 | 2019 | 855 | 0.550 |
Why?
| Granulocyte Colony-Stimulating Factor | 6 | 2021 | 73 | 0.540 |
Why?
| Immunotherapy | 5 | 2024 | 596 | 0.530 |
Why?
| HLA-DQ Antigens | 11 | 2019 | 179 | 0.530 |
Why?
| Mycophenolic Acid | 3 | 2012 | 110 | 0.500 |
Why?
| Peptides | 5 | 2024 | 926 | 0.480 |
Why?
| Autoimmune Diseases | 10 | 2017 | 428 | 0.480 |
Why?
| Chromogranin A | 2 | 2024 | 42 | 0.470 |
Why?
| Steroid 21-Hydroxylase | 5 | 2012 | 30 | 0.460 |
Why?
| Monocytes | 4 | 2016 | 553 | 0.460 |
Why?
| Immunoglobulin G | 6 | 2018 | 851 | 0.460 |
Why?
| Female | 90 | 2025 | 68751 | 0.460 |
Why?
| Male | 83 | 2025 | 63691 | 0.450 |
Why?
| Glutamate Decarboxylase | 9 | 2022 | 166 | 0.450 |
Why?
| Mice, Inbred NOD | 16 | 2023 | 587 | 0.450 |
Why?
| Biomarkers | 13 | 2024 | 3969 | 0.440 |
Why?
| Cytokines | 9 | 2018 | 2022 | 0.430 |
Why?
| Vaccines, DNA | 1 | 2013 | 28 | 0.430 |
Why?
| Cystic Fibrosis | 3 | 2012 | 1066 | 0.410 |
Why?
| Interferon-gamma | 6 | 2021 | 773 | 0.400 |
Why?
| Immunomodulation | 1 | 2013 | 92 | 0.400 |
Why?
| Myeloid Cells | 1 | 2014 | 142 | 0.400 |
Why?
| alpha 1-Antitrypsin | 1 | 2014 | 107 | 0.400 |
Why?
| Immunologic Memory | 7 | 2019 | 349 | 0.400 |
Why?
| T-Lymphocyte Subsets | 8 | 2018 | 412 | 0.400 |
Why?
| Hypoglycemia | 6 | 2009 | 427 | 0.370 |
Why?
| Disease Progression | 16 | 2021 | 2628 | 0.370 |
Why?
| Dendritic Cells | 2 | 2014 | 481 | 0.360 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 338 | 0.350 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2021 | 63 | 0.340 |
Why?
| Diabetes Mellitus | 2 | 2023 | 1003 | 0.330 |
Why?
| Immunoconjugates | 4 | 2014 | 104 | 0.320 |
Why?
| Histocompatibility Antigens Class I | 6 | 2011 | 200 | 0.320 |
Why?
| CD3 Complex | 5 | 2019 | 102 | 0.320 |
Why?
| HLA-DR3 Antigen | 5 | 2022 | 80 | 0.320 |
Why?
| Lymphocyte Activation | 7 | 2025 | 1110 | 0.310 |
Why?
| HLA-DR Antigens | 8 | 2018 | 223 | 0.310 |
Why?
| Area Under Curve | 9 | 2024 | 306 | 0.310 |
Why?
| Clonal Anergy | 3 | 2018 | 52 | 0.290 |
Why?
| Antibodies, Monoclonal | 5 | 2010 | 1368 | 0.290 |
Why?
| Insulin, Regular, Human | 3 | 2024 | 43 | 0.280 |
Why?
| Cation Transport Proteins | 3 | 2017 | 131 | 0.270 |
Why?
| Toll-Like Receptors | 3 | 2014 | 179 | 0.270 |
Why?
| Age of Onset | 6 | 2020 | 494 | 0.260 |
Why?
| Double-Blind Method | 12 | 2021 | 1875 | 0.260 |
Why?
| Zinc Transporter 8 | 4 | 2021 | 87 | 0.250 |
Why?
| Time Factors | 10 | 2020 | 6545 | 0.250 |
Why?
| Receptors, Interleukin-2 | 2 | 2006 | 64 | 0.250 |
Why?
| Middle Aged | 36 | 2025 | 31165 | 0.240 |
Why?
| Animals | 30 | 2024 | 35404 | 0.240 |
Why?
| Glucose Tolerance Test | 6 | 2025 | 355 | 0.240 |
Why?
| Genetic Predisposition to Disease | 10 | 2025 | 2271 | 0.230 |
Why?
| Antigen Presentation | 3 | 2018 | 207 | 0.230 |
Why?
| Insulin, Isophane | 1 | 2004 | 21 | 0.230 |
Why?
| Software | 2 | 2008 | 606 | 0.230 |
Why?
| Precision Medicine | 3 | 2023 | 385 | 0.220 |
Why?
| T-Lymphocytes, Regulatory | 6 | 2023 | 373 | 0.220 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 3 | 2013 | 86 | 0.220 |
Why?
| Protein Precursors | 2 | 2016 | 128 | 0.210 |
Why?
| Mice | 24 | 2024 | 16982 | 0.210 |
Why?
| Pregnancy in Diabetics | 2 | 2003 | 118 | 0.210 |
Why?
| Child, Preschool | 20 | 2024 | 10487 | 0.210 |
Why?
| Immunotherapy, Active | 2 | 2014 | 9 | 0.210 |
Why?
| Diabetic Ketoacidosis | 2 | 2024 | 197 | 0.200 |
Why?
| Plasmids | 3 | 2013 | 360 | 0.200 |
Why?
| Polyethylene Glycols | 3 | 2018 | 612 | 0.200 |
Why?
| Treatment Outcome | 12 | 2024 | 10221 | 0.200 |
Why?
| Histocompatibility Testing | 4 | 2013 | 121 | 0.200 |
Why?
| Interleukin-1beta | 3 | 2014 | 369 | 0.190 |
Why?
| Islets of Langerhans Transplantation | 2 | 2015 | 63 | 0.190 |
Why?
| Epitopes, T-Lymphocyte | 4 | 2011 | 186 | 0.190 |
Why?
| Lymphocyte Depletion | 2 | 2013 | 134 | 0.190 |
Why?
| Haplotypes | 6 | 2022 | 474 | 0.190 |
Why?
| Immune Tolerance | 2 | 2017 | 356 | 0.190 |
Why?
| Methyldopa | 2 | 2019 | 7 | 0.190 |
Why?
| Recombinant Fusion Proteins | 2 | 2015 | 650 | 0.190 |
Why?
| Imatinib Mesylate | 1 | 2021 | 75 | 0.180 |
Why?
| Receptors, Antigen, T-Cell | 5 | 2022 | 707 | 0.180 |
Why?
| Necrobiosis Lipoidica | 1 | 2001 | 2 | 0.180 |
Why?
| Hyperglycemia | 1 | 2024 | 327 | 0.180 |
Why?
| Asymptomatic Diseases | 1 | 2021 | 84 | 0.180 |
Why?
| Histocompatibility Antigens Class II | 3 | 2011 | 363 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 5 | 2019 | 2014 | 0.170 |
Why?
| Platelet-Derived Growth Factor | 1 | 2001 | 89 | 0.170 |
Why?
| History, 21st Century | 2 | 2018 | 185 | 0.170 |
Why?
| Administration, Oral | 2 | 2024 | 787 | 0.170 |
Why?
| History, 20th Century | 2 | 2018 | 293 | 0.170 |
Why?
| Biomarkers, Pharmacological | 1 | 2020 | 26 | 0.170 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 50 | 0.170 |
Why?
| Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 12 | 0.170 |
Why?
| Cytomegalovirus | 2 | 2018 | 154 | 0.160 |
Why?
| Biological Variation, Population | 1 | 2019 | 21 | 0.160 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2025 | 2062 | 0.160 |
Why?
| Hepatitis Delta Virus | 3 | 1994 | 7 | 0.160 |
Why?
| Epitopes | 5 | 2024 | 474 | 0.160 |
Why?
| Luminescence | 2 | 2016 | 37 | 0.160 |
Why?
| Graves Disease | 2 | 2017 | 34 | 0.160 |
Why?
| Th2 Cells | 2 | 2014 | 171 | 0.160 |
Why?
| Gastrointestinal Microbiome | 2 | 2018 | 641 | 0.160 |
Why?
| Forkhead Transcription Factors | 3 | 2016 | 184 | 0.150 |
Why?
| Family | 3 | 2025 | 646 | 0.150 |
Why?
| Cytoprotection | 1 | 2018 | 56 | 0.150 |
Why?
| Biomedical Research | 2 | 2018 | 640 | 0.150 |
Why?
| Immunity, Cellular | 2 | 2018 | 265 | 0.140 |
Why?
| Thyroiditis, Autoimmune | 1 | 2017 | 15 | 0.140 |
Why?
| Diabetes Mellitus, Experimental | 2 | 1990 | 183 | 0.140 |
Why?
| HLA-A2 Antigen | 1 | 2017 | 48 | 0.140 |
Why?
| Abatacept | 5 | 2023 | 46 | 0.140 |
Why?
| Twins, Dizygotic | 1 | 2018 | 181 | 0.140 |
Why?
| HLA-DR4 Antigen | 4 | 2022 | 78 | 0.140 |
Why?
| Inflammation | 4 | 2018 | 2748 | 0.140 |
Why?
| Twins, Monozygotic | 1 | 2018 | 209 | 0.140 |
Why?
| Thyroid Gland | 1 | 2017 | 95 | 0.140 |
Why?
| Treatment Failure | 1 | 2018 | 339 | 0.140 |
Why?
| Antibody-Producing Cells | 1 | 2017 | 30 | 0.140 |
Why?
| Magnetic Fields | 1 | 2017 | 22 | 0.140 |
Why?
| Th1 Cells | 2 | 2009 | 137 | 0.130 |
Why?
| Cell Separation | 2 | 2017 | 315 | 0.130 |
Why?
| Regeneration | 1 | 1998 | 182 | 0.130 |
Why?
| Dysbiosis | 1 | 2018 | 170 | 0.130 |
Why?
| Cytomegalovirus Infections | 1 | 2018 | 189 | 0.130 |
Why?
| Antibody Formation | 1 | 2018 | 291 | 0.130 |
Why?
| Influenza, Human | 1 | 2022 | 602 | 0.130 |
Why?
| Follow-Up Studies | 8 | 2021 | 4892 | 0.130 |
Why?
| Trans-Activators | 1 | 1998 | 392 | 0.130 |
Why?
| RNA, Catalytic | 2 | 1994 | 185 | 0.120 |
Why?
| Nanoparticles | 2 | 2017 | 376 | 0.120 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 886 | 0.120 |
Why?
| Tuftsin | 3 | 1983 | 4 | 0.120 |
Why?
| Host-Pathogen Interactions | 1 | 2018 | 355 | 0.120 |
Why?
| Homeodomain Proteins | 1 | 1998 | 493 | 0.120 |
Why?
| Dermatologic Agents | 1 | 2015 | 65 | 0.120 |
Why?
| Drug Therapy, Combination | 3 | 2018 | 1042 | 0.110 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2024 | 1368 | 0.110 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 336 | 0.110 |
Why?
| Phenotype | 2 | 2019 | 3062 | 0.110 |
Why?
| Law Enforcement | 1 | 2014 | 39 | 0.110 |
Why?
| Crime | 1 | 2014 | 57 | 0.110 |
Why?
| Graft Rejection | 2 | 2015 | 598 | 0.110 |
Why?
| Risk Factors | 12 | 2018 | 9787 | 0.110 |
Why?
| Criminals | 1 | 2014 | 36 | 0.110 |
Why?
| Withholding Treatment | 1 | 2013 | 71 | 0.100 |
Why?
| Primary Cell Culture | 1 | 2013 | 164 | 0.100 |
Why?
| Transglutaminases | 1 | 2013 | 153 | 0.100 |
Why?
| Cytotoxicity, Immunologic | 2 | 2013 | 220 | 0.100 |
Why?
| Adjuvants, Immunologic | 1 | 2014 | 222 | 0.100 |
Why?
| Gene Expression | 2 | 2013 | 1465 | 0.100 |
Why?
| Pancreatectomy | 1 | 2015 | 242 | 0.100 |
Why?
| Reproducibility of Results | 3 | 2009 | 3084 | 0.100 |
Why?
| Adaptive Immunity | 1 | 2013 | 161 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2009 | 1844 | 0.100 |
Why?
| Nucleic Acid Conformation | 3 | 1994 | 706 | 0.100 |
Why?
| Communicable Diseases | 1 | 2014 | 152 | 0.100 |
Why?
| DNA, Viral | 1 | 1994 | 347 | 0.090 |
Why?
| Receptors, Immunologic | 2 | 1983 | 216 | 0.090 |
Why?
| Diabetic Angiopathies | 2 | 2010 | 261 | 0.090 |
Why?
| Proportional Hazards Models | 3 | 2021 | 1199 | 0.090 |
Why?
| Flow Cytometry | 4 | 2019 | 1160 | 0.090 |
Why?
| Alleles | 5 | 2011 | 843 | 0.090 |
Why?
| Thyroiditis | 1 | 1991 | 3 | 0.090 |
Why?
| Polymorphism, Genetic | 3 | 2010 | 636 | 0.090 |
Why?
| Down-Regulation | 1 | 2014 | 631 | 0.090 |
Why?
| Herpesviridae Infections | 1 | 2012 | 141 | 0.090 |
Why?
| Epstein-Barr Virus Infections | 1 | 2012 | 95 | 0.090 |
Why?
| Cross-Sectional Studies | 6 | 2023 | 5083 | 0.090 |
Why?
| Cells, Cultured | 7 | 2017 | 4102 | 0.090 |
Why?
| Lymphocyte Count | 3 | 2019 | 148 | 0.090 |
Why?
| Recombinant Proteins | 3 | 2018 | 1310 | 0.090 |
Why?
| HLA-B Antigens | 1 | 2011 | 62 | 0.090 |
Why?
| Interleukin-6 | 2 | 2012 | 724 | 0.090 |
Why?
| Organophosphorus Compounds | 1 | 2011 | 78 | 0.090 |
Why?
| Cryopreservation | 1 | 2011 | 94 | 0.090 |
Why?
| Pilot Projects | 3 | 2021 | 1594 | 0.090 |
Why?
| Glycine | 1 | 2011 | 166 | 0.090 |
Why?
| Endocrine Cells | 1 | 2010 | 7 | 0.090 |
Why?
| Drug Delivery Systems | 1 | 2013 | 337 | 0.090 |
Why?
| Transplantation Immunology | 1 | 1990 | 34 | 0.080 |
Why?
| Insulin, Long-Acting | 3 | 2004 | 62 | 0.080 |
Why?
| HLA Antigens | 4 | 2022 | 235 | 0.080 |
Why?
| Single-Cell Analysis | 2 | 2025 | 274 | 0.080 |
Why?
| Inflammation Mediators | 2 | 2010 | 505 | 0.080 |
Why?
| Insulin Glargine | 3 | 2004 | 81 | 0.080 |
Why?
| Genotype | 5 | 2015 | 1829 | 0.080 |
Why?
| Molecular Sequence Data | 8 | 2015 | 2833 | 0.080 |
Why?
| Muromonab-CD3 | 1 | 2009 | 20 | 0.080 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 2009 | 170 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 836 | 0.080 |
Why?
| Prognosis | 4 | 2021 | 3772 | 0.080 |
Why?
| Adrenocorticotropic Hormone | 2 | 2012 | 133 | 0.080 |
Why?
| Mental Health Services | 1 | 2014 | 404 | 0.080 |
Why?
| Amino Acid Sequence | 7 | 2015 | 2057 | 0.080 |
Why?
| Interleukin-17 | 1 | 2009 | 110 | 0.080 |
Why?
| Receptors, Chemokine | 2 | 2007 | 45 | 0.080 |
Why?
| Antigens | 3 | 2023 | 356 | 0.080 |
Why?
| Bacteria | 1 | 2015 | 814 | 0.080 |
Why?
| Vitamin D Deficiency | 1 | 2010 | 177 | 0.070 |
Why?
| Insulin Infusion Systems | 2 | 2004 | 363 | 0.070 |
Why?
| Calcinosis | 1 | 2010 | 232 | 0.070 |
Why?
| Immunodominant Epitopes | 2 | 2006 | 28 | 0.070 |
Why?
| Remission Induction | 2 | 2018 | 274 | 0.070 |
Why?
| Platelet Membrane Glycoprotein IIb | 1 | 2007 | 4 | 0.070 |
Why?
| Enzyme-Linked Immunospot Assay | 3 | 2011 | 36 | 0.070 |
Why?
| Homicide | 1 | 1988 | 61 | 0.070 |
Why?
| Hydrocortisone | 2 | 2012 | 306 | 0.070 |
Why?
| Regression Analysis | 1 | 2010 | 997 | 0.070 |
Why?
| Consensus | 2 | 2023 | 617 | 0.070 |
Why?
| Equipment Design | 1 | 2009 | 514 | 0.070 |
Why?
| Case-Control Studies | 5 | 2016 | 3381 | 0.070 |
Why?
| Safety | 1 | 2009 | 335 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2009 | 4076 | 0.070 |
Why?
| Radioimmunoassay | 2 | 2017 | 175 | 0.070 |
Why?
| Rituximab | 3 | 2013 | 164 | 0.070 |
Why?
| CD40 Antigens | 1 | 2007 | 88 | 0.070 |
Why?
| Killer Cells, Natural | 2 | 2016 | 426 | 0.070 |
Why?
| Microsatellite Repeats | 2 | 2009 | 163 | 0.070 |
Why?
| Receptors, Interleukin-7 | 1 | 2006 | 27 | 0.060 |
Why?
| CD4 Lymphocyte Count | 3 | 2015 | 267 | 0.060 |
Why?
| Infant | 5 | 2024 | 8987 | 0.060 |
Why?
| Atherosclerosis | 1 | 2010 | 402 | 0.060 |
Why?
| Hybridomas | 2 | 2004 | 235 | 0.060 |
Why?
| Proteins | 2 | 2018 | 944 | 0.060 |
Why?
| Isoenzymes | 2 | 2004 | 301 | 0.060 |
Why?
| Diabetic Retinopathy | 2 | 2005 | 179 | 0.060 |
Why?
| Mutation | 4 | 2015 | 3705 | 0.060 |
Why?
| Disease Susceptibility | 2 | 2019 | 334 | 0.060 |
Why?
| Mental Disorders | 1 | 2014 | 1035 | 0.060 |
Why?
| Protein Tyrosine Phosphatases | 2 | 2004 | 165 | 0.060 |
Why?
| Signal Transduction | 3 | 2019 | 4935 | 0.060 |
Why?
| Gene Frequency | 3 | 2016 | 500 | 0.060 |
Why?
| Prevalence | 3 | 2024 | 2563 | 0.060 |
Why?
| Chemokines, CXC | 1 | 2005 | 70 | 0.060 |
Why?
| Urban Population | 1 | 1988 | 443 | 0.060 |
Why?
| Risk | 3 | 2019 | 855 | 0.060 |
Why?
| Acetamides | 1 | 2005 | 36 | 0.060 |
Why?
| Major Histocompatibility Complex | 2 | 2002 | 229 | 0.060 |
Why?
| Exanthema | 2 | 2019 | 74 | 0.060 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2025 | 126 | 0.060 |
Why?
| Blood Coagulation Factors | 1 | 1984 | 53 | 0.060 |
Why?
| Coronary Artery Disease | 1 | 2010 | 680 | 0.060 |
Why?
| Immunophenotyping | 2 | 2018 | 310 | 0.050 |
Why?
| Feces | 2 | 2018 | 442 | 0.050 |
Why?
| Immunoglobulin Fragments | 1 | 1983 | 11 | 0.050 |
Why?
| Niacinamide | 1 | 2004 | 75 | 0.050 |
Why?
| Age Factors | 3 | 2017 | 3153 | 0.050 |
Why?
| Genes, MHC Class II | 2 | 2002 | 73 | 0.050 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 546 | 0.050 |
Why?
| Placebos | 2 | 2013 | 201 | 0.050 |
Why?
| Immunoassay | 1 | 2003 | 108 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 373 | 0.050 |
Why?
| Genetic Association Studies | 1 | 2025 | 357 | 0.050 |
Why?
| Tissue Donors | 1 | 2006 | 391 | 0.050 |
Why?
| Cell Survival | 2 | 2019 | 1086 | 0.050 |
Why?
| Interleukin-4 | 2 | 2002 | 212 | 0.050 |
Why?
| Mice, Knockout | 1 | 2009 | 2888 | 0.050 |
Why?
| Antigens, CD1 | 1 | 2002 | 58 | 0.050 |
Why?
| Siblings | 2 | 2018 | 216 | 0.050 |
Why?
| Receptors, CXCR3 | 2 | 2016 | 16 | 0.050 |
Why?
| Antibody Affinity | 2 | 2016 | 59 | 0.050 |
Why?
| Cell Differentiation | 1 | 2009 | 1900 | 0.050 |
Why?
| Canada | 2 | 2014 | 353 | 0.050 |
Why?
| Cell Proliferation | 2 | 2009 | 2378 | 0.050 |
Why?
| Pyrimidines | 1 | 2005 | 458 | 0.050 |
Why?
| Preconception Care | 1 | 2002 | 41 | 0.050 |
Why?
| Denmark | 2 | 2014 | 45 | 0.050 |
Why?
| Labor, Obstetric | 1 | 2002 | 59 | 0.050 |
Why?
| Diseases in Twins | 2 | 2018 | 175 | 0.050 |
Why?
| Reference Values | 3 | 2009 | 796 | 0.050 |
Why?
| Pancreas | 2 | 2018 | 305 | 0.040 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2001 | 35 | 0.040 |
Why?
| Algorithms | 1 | 2008 | 1616 | 0.040 |
Why?
| Bacterial Proteins | 2 | 2018 | 838 | 0.040 |
Why?
| Administration, Topical | 1 | 2001 | 147 | 0.040 |
Why?
| Pregnancy Outcome | 1 | 2003 | 392 | 0.040 |
Why?
| Vitamin D | 1 | 2004 | 380 | 0.040 |
Why?
| Venoms | 1 | 2020 | 29 | 0.040 |
Why?
| Rats, Inbred BB | 2 | 1991 | 6 | 0.040 |
Why?
| Kinetics | 4 | 1994 | 1645 | 0.040 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2020 | 14 | 0.040 |
Why?
| Membrane Proteins | 2 | 2004 | 1119 | 0.040 |
Why?
| HLA-DR2 Antigen | 1 | 1999 | 7 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2019 | 82 | 0.040 |
Why?
| Antibodies, Heterophile | 1 | 1999 | 14 | 0.040 |
Why?
| Hemorrhage | 1 | 1984 | 679 | 0.040 |
Why?
| ROC Curve | 1 | 2021 | 503 | 0.040 |
Why?
| Lymphocytes | 1 | 2002 | 377 | 0.040 |
Why?
| HLA-DRB1 Chains | 3 | 2009 | 108 | 0.040 |
Why?
| Interleukin-7 | 1 | 2019 | 59 | 0.040 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2007 | 47 | 0.040 |
Why?
| HLA-A Antigens | 2 | 2011 | 53 | 0.040 |
Why?
| CD4-CD8 Ratio | 1 | 2019 | 22 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2023 | 713 | 0.040 |
Why?
| Mice, Inbred BALB C | 4 | 2011 | 1248 | 0.040 |
Why?
| Lymphopenia | 1 | 2019 | 60 | 0.040 |
Why?
| Prospective Studies | 4 | 2016 | 7145 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 486 | 0.040 |
Why?
| Databases, Factual | 1 | 2004 | 1269 | 0.040 |
Why?
| Leg | 1 | 2001 | 240 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 331 | 0.040 |
Why?
| Methylation | 1 | 2019 | 228 | 0.040 |
Why?
| RNA, Viral | 2 | 1992 | 620 | 0.040 |
Why?
| Seroconversion | 1 | 2018 | 46 | 0.040 |
Why?
| Mucosal-Associated Invariant T Cells | 1 | 2018 | 27 | 0.040 |
Why?
| Insulin Lispro | 3 | 2004 | 39 | 0.040 |
Why?
| Macrophages | 2 | 1983 | 1489 | 0.040 |
Why?
| Meals | 1 | 2020 | 119 | 0.040 |
Why?
| Aged | 7 | 2014 | 22101 | 0.040 |
Why?
| Therapies, Investigational | 1 | 2018 | 17 | 0.040 |
Why?
| Wound Healing | 1 | 2001 | 308 | 0.040 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2018 | 11 | 0.040 |
Why?
| B7-2 Antigen | 1 | 2017 | 27 | 0.040 |
Why?
| Seroepidemiologic Studies | 1 | 2018 | 157 | 0.040 |
Why?
| Colorado | 2 | 2024 | 4405 | 0.040 |
Why?
| Base Sequence | 4 | 1994 | 2142 | 0.040 |
Why?
| Ikaros Transcription Factor | 1 | 2018 | 23 | 0.040 |
Why?
| Risk Assessment | 2 | 2018 | 3260 | 0.040 |
Why?
| Glucose | 1 | 2023 | 1003 | 0.040 |
Why?
| Cell Death | 1 | 2019 | 352 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2018 | 2135 | 0.030 |
Why?
| Patient Care Planning | 1 | 2018 | 146 | 0.030 |
Why?
| Drug Discovery | 1 | 2018 | 131 | 0.030 |
Why?
| Rats | 3 | 1991 | 5485 | 0.030 |
Why?
| Antigens, CD | 2 | 2014 | 487 | 0.030 |
Why?
| United States | 4 | 2015 | 13906 | 0.030 |
Why?
| Retrospective Studies | 4 | 2025 | 14525 | 0.030 |
Why?
| Structure-Activity Relationship | 2 | 2011 | 547 | 0.030 |
Why?
| Clone Cells | 3 | 2004 | 262 | 0.030 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.030 |
Why?
| Genetic Markers | 1 | 1998 | 334 | 0.030 |
Why?
| Twins | 1 | 2018 | 247 | 0.030 |
Why?
| CD56 Antigen | 1 | 2016 | 36 | 0.030 |
Why?
| Luminescent Measurements | 1 | 2017 | 76 | 0.030 |
Why?
| Receptors, IgG | 1 | 2016 | 73 | 0.030 |
Why?
| HLA-DQ beta-Chains | 2 | 2009 | 61 | 0.030 |
Why?
| Leukocyte Common Antigens | 2 | 2007 | 82 | 0.030 |
Why?
| Environment | 1 | 2018 | 345 | 0.030 |
Why?
| Cell Count | 1 | 2017 | 318 | 0.030 |
Why?
| Somalia | 1 | 2016 | 10 | 0.030 |
Why?
| Antibody Specificity | 2 | 2007 | 185 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2012 | 1950 | 0.030 |
Why?
| Forecasting | 1 | 1998 | 361 | 0.030 |
Why?
| Orphan Drug Production | 1 | 2015 | 5 | 0.030 |
Why?
| Cohort Studies | 3 | 2015 | 5434 | 0.030 |
Why?
| Organ Specificity | 2 | 2007 | 295 | 0.030 |
Why?
| Cities | 1 | 2016 | 105 | 0.030 |
Why?
| Minnesota | 1 | 2016 | 149 | 0.030 |
Why?
| Intestines | 1 | 2018 | 349 | 0.030 |
Why?
| Immunity, Humoral | 1 | 2016 | 118 | 0.030 |
Why?
| Ethics, Medical | 1 | 2015 | 78 | 0.030 |
Why?
| Immunity, Active | 1 | 2014 | 10 | 0.030 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 371 | 0.030 |
Why?
| Immunity, Innate | 2 | 2009 | 804 | 0.030 |
Why?
| Early Diagnosis | 1 | 2015 | 233 | 0.030 |
Why?
| Proline | 1 | 1994 | 76 | 0.030 |
Why?
| Immunoglobulins | 1 | 2014 | 162 | 0.030 |
Why?
| Opportunistic Infections | 1 | 2014 | 46 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2015 | 213 | 0.030 |
Why?
| Single-Blind Method | 1 | 2014 | 271 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 1994 | 342 | 0.030 |
Why?
| Cloning, Molecular | 1 | 2014 | 524 | 0.030 |
Why?
| Drug Combinations | 1 | 2014 | 331 | 0.030 |
Why?
| Sequence Deletion | 1 | 1994 | 179 | 0.030 |
Why?
| Europe | 1 | 2014 | 363 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 277 | 0.030 |
Why?
| Mutagenesis | 1 | 1994 | 179 | 0.030 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2013 | 41 | 0.030 |
Why?
| Escherichia coli Proteins | 1 | 1994 | 179 | 0.030 |
Why?
| Formamides | 1 | 1992 | 6 | 0.030 |
Why?
| Interleukin-10 | 1 | 2015 | 304 | 0.030 |
Why?
| Body Mass Index | 1 | 2021 | 2274 | 0.030 |
Why?
| Transcription, Genetic | 3 | 1994 | 1416 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2015 | 524 | 0.030 |
Why?
| Herpesviridae | 1 | 2012 | 22 | 0.030 |
Why?
| Pregnancy | 2 | 2003 | 6412 | 0.020 |
Why?
| Immunocompromised Host | 1 | 2014 | 199 | 0.020 |
Why?
| Interleukins | 1 | 2014 | 241 | 0.020 |
Why?
| Renin | 1 | 2012 | 32 | 0.020 |
Why?
| Lymph Nodes | 2 | 2006 | 471 | 0.020 |
Why?
| Postprandial Period | 1 | 2013 | 105 | 0.020 |
Why?
| Graft Survival | 1 | 2015 | 514 | 0.020 |
Why?
| RNA, Antisense | 1 | 1992 | 16 | 0.020 |
Why?
| Virus Activation | 1 | 2012 | 88 | 0.020 |
Why?
| Gene Expression Regulation | 2 | 2014 | 2545 | 0.020 |
Why?
| Proteomics | 1 | 2018 | 1058 | 0.020 |
Why?
| Herpesvirus 4, Human | 1 | 2012 | 157 | 0.020 |
Why?
| Ligands | 2 | 2005 | 621 | 0.020 |
Why?
| Societies, Medical | 1 | 2015 | 744 | 0.020 |
Why?
| HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| Sample Size | 1 | 2011 | 116 | 0.020 |
Why?
| Phagocytosis | 2 | 1983 | 362 | 0.020 |
Why?
| Cognition Disorders | 1 | 2015 | 505 | 0.020 |
Why?
| Thallium Radioisotopes | 1 | 1991 | 8 | 0.020 |
Why?
| Receptors, Cell Surface | 2 | 1983 | 381 | 0.020 |
Why?
| RNA Splicing | 1 | 1992 | 259 | 0.020 |
Why?
| Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.020 |
Why?
| Small Molecule Libraries | 1 | 2011 | 86 | 0.020 |
Why?
| HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| Isoantigens | 1 | 1990 | 14 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| Mass Screening | 1 | 2018 | 1192 | 0.020 |
Why?
| Polymerase Chain Reaction | 2 | 2009 | 1033 | 0.020 |
Why?
| Amino Acid Substitution | 2 | 2002 | 284 | 0.020 |
Why?
| Rats, Inbred Strains | 1 | 1990 | 368 | 0.020 |
Why?
| Spleen | 3 | 2002 | 508 | 0.020 |
Why?
| Linkage Disequilibrium | 1 | 2010 | 257 | 0.020 |
Why?
| Chemokines | 1 | 2010 | 227 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2010 | 379 | 0.020 |
Why?
| Pedigree | 1 | 2010 | 483 | 0.020 |
Why?
| Homozygote | 1 | 2009 | 195 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2016 | 2724 | 0.020 |
Why?
| Immunoblotting | 1 | 2009 | 306 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 1990 | 402 | 0.020 |
Why?
| Coculture Techniques | 1 | 2009 | 224 | 0.020 |
Why?
| Nausea | 1 | 2009 | 111 | 0.020 |
Why?
| Logistic Models | 1 | 2014 | 1988 | 0.020 |
Why?
| Vomiting | 1 | 2009 | 129 | 0.020 |
Why?
| Interferon-alpha | 1 | 2009 | 194 | 0.020 |
Why?
| Immunoglobulin M | 1 | 2009 | 276 | 0.020 |
Why?
| Coronary Disease | 1 | 1991 | 385 | 0.020 |
Why?
| Genetic Vectors | 1 | 2009 | 312 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 1988 | 408 | 0.020 |
Why?
| DNA | 1 | 1994 | 1406 | 0.020 |
Why?
| DNA Methylation | 1 | 2013 | 606 | 0.020 |
Why?
| Immunotherapy, Adoptive | 1 | 1991 | 300 | 0.020 |
Why?
| Cell Line | 2 | 2004 | 2779 | 0.020 |
Why?
| Fever | 1 | 2009 | 298 | 0.020 |
Why?
| Exercise Test | 1 | 1991 | 614 | 0.020 |
Why?
| Up-Regulation | 1 | 2010 | 836 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 1994 | 1441 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2009 | 198 | 0.020 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 82 | 0.020 |
Why?
| Antisocial Personality Disorder | 1 | 1988 | 163 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 372 | 0.020 |
Why?
| Models, Molecular | 1 | 2011 | 1488 | 0.020 |
Why?
| NF-kappa B | 1 | 2010 | 666 | 0.020 |
Why?
| Chromogranins | 1 | 2006 | 13 | 0.020 |
Why?
| Social Environment | 1 | 1988 | 293 | 0.020 |
Why?
| Phosphorylation | 1 | 2010 | 1716 | 0.020 |
Why?
| Psychotic Disorders | 1 | 1988 | 151 | 0.020 |
Why?
| Hemodynamics | 1 | 1991 | 1091 | 0.020 |
Why?
| Mice, Inbred C3H | 2 | 1983 | 271 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 5468 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 756 | 0.020 |
Why?
| Chemokine CXCL11 | 1 | 2005 | 3 | 0.010 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 14 | 0.010 |
Why?
| Glucagon | 1 | 2006 | 105 | 0.010 |
Why?
| Keratins | 1 | 2006 | 175 | 0.010 |
Why?
| Iodide Peroxidase | 1 | 2005 | 28 | 0.010 |
Why?
| Thyroglobulin | 1 | 2005 | 27 | 0.010 |
Why?
| Alprostadil | 1 | 2005 | 32 | 0.010 |
Why?
| Chemokine CXCL9 | 1 | 2005 | 27 | 0.010 |
Why?
| Chemokine CXCL10 | 1 | 2005 | 36 | 0.010 |
Why?
| Lupus Coagulation Inhibitor | 1 | 1984 | 5 | 0.010 |
Why?
| Antigenic Variation | 1 | 2004 | 10 | 0.010 |
Why?
| Fathers | 1 | 2005 | 50 | 0.010 |
Why?
| Interpersonal Relations | 1 | 1988 | 395 | 0.010 |
Why?
| Dinoprostone | 1 | 2005 | 187 | 0.010 |
Why?
| Mice, Inbred CBA | 1 | 2004 | 53 | 0.010 |
Why?
| Tetanus Toxin | 1 | 2003 | 6 | 0.010 |
Why?
| Infusion Pumps, Implantable | 1 | 2004 | 22 | 0.010 |
Why?
| Chaperonin 60 | 1 | 2003 | 14 | 0.010 |
Why?
| Insulin Aspart | 1 | 2004 | 26 | 0.010 |
Why?
| Quality of Life | 1 | 2015 | 2694 | 0.010 |
Why?
| Homeostasis | 1 | 2007 | 605 | 0.010 |
Why?
| Injections, Subcutaneous | 1 | 2004 | 146 | 0.010 |
Why?
| Postoperative Complications | 1 | 2015 | 2470 | 0.010 |
Why?
| Indicators and Reagents | 1 | 1983 | 109 | 0.010 |
Why?
| Fibrosis | 1 | 2006 | 526 | 0.010 |
Why?
| Biological Assay | 1 | 1983 | 119 | 0.010 |
Why?
| Fetal Macrosomia | 1 | 2003 | 62 | 0.010 |
Why?
| Models, Biological | 1 | 1990 | 1724 | 0.010 |
Why?
| Binding, Competitive | 1 | 1983 | 206 | 0.010 |
Why?
| Antigens, CD1d | 1 | 2002 | 66 | 0.010 |
Why?
| Congenital Abnormalities | 1 | 2003 | 76 | 0.010 |
Why?
| C-Reactive Protein | 1 | 2005 | 401 | 0.010 |
Why?
| Interleukin-2 | 1 | 2004 | 437 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2004 | 766 | 0.010 |
Why?
| Insulin Resistance | 1 | 2010 | 1168 | 0.010 |
Why?
| Antigens, Surface | 1 | 2002 | 152 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 82 | 0.010 |
Why?
| Cell Division | 1 | 2004 | 790 | 0.010 |
Why?
| Albuminuria | 1 | 2003 | 183 | 0.010 |
Why?
| Sex Factors | 1 | 1988 | 1973 | 0.010 |
Why?
| CTLA-4 Antigen | 1 | 2002 | 87 | 0.010 |
Why?
| Celiac Disease | 1 | 2005 | 286 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2006 | 1690 | 0.010 |
Why?
| Alcoholism | 1 | 1988 | 766 | 0.010 |
Why?
| Multivariate Analysis | 1 | 2005 | 1500 | 0.010 |
Why?
| HLA-DQ alpha-Chains | 1 | 1999 | 16 | 0.010 |
Why?
| Gestational Age | 1 | 2003 | 874 | 0.010 |
Why?
| Glutamine | 1 | 2000 | 100 | 0.010 |
Why?
| Birth Weight | 1 | 2003 | 505 | 0.010 |
Why?
| Body Weight | 1 | 2004 | 947 | 0.010 |
Why?
| Alanine | 1 | 2000 | 143 | 0.010 |
Why?
| Aging | 2 | 2007 | 1774 | 0.010 |
Why?
| Substance-Related Disorders | 1 | 1988 | 1022 | 0.010 |
Why?
| Mothers | 1 | 2005 | 731 | 0.010 |
Why?
| Incidence | 1 | 2005 | 2644 | 0.010 |
Why?
| Cell Line, Tumor | 1 | 2005 | 3184 | 0.010 |
Why?
| Trifluoroethanol | 1 | 1994 | 1 | 0.010 |
Why?
| Survival Rate | 1 | 1999 | 1872 | 0.010 |
Why?
| Polydeoxyribonucleotides | 1 | 1994 | 13 | 0.010 |
Why?
| Sodium Dodecyl Sulfate | 1 | 1994 | 22 | 0.010 |
Why?
| Electrophoresis, Agar Gel | 1 | 1994 | 25 | 0.010 |
Why?
| Circular Dichroism | 1 | 1994 | 147 | 0.010 |
Why?
| DNA, Single-Stranded | 1 | 1994 | 114 | 0.010 |
Why?
| Genes, Viral | 1 | 1992 | 82 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 338 | 0.010 |
Why?
| Genome, Viral | 1 | 1992 | 128 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1991 | 122 | 0.010 |
Why?
| Computer Simulation | 1 | 1994 | 940 | 0.010 |
Why?
| Temperature | 1 | 1992 | 635 | 0.000 |
Why?
| Neoplasms | 1 | 1983 | 2454 | 0.000 |
Why?
| Lethal Dose 50 | 1 | 1983 | 15 | 0.000 |
Why?
| Fibrosarcoma | 1 | 1983 | 21 | 0.000 |
Why?
| Leukocytosis | 1 | 1983 | 31 | 0.000 |
Why?
| Neoplasm Transplantation | 1 | 1983 | 253 | 0.000 |
Why?
| Leukocyte Count | 1 | 1983 | 326 | 0.000 |
Why?
| Hypertension | 1 | 1991 | 1242 | 0.000 |
Why?
| Dogs | 1 | 1983 | 385 | 0.000 |
Why?
|
|
Gottlieb's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|